Biosimilar参照抗体

在生物药研发中,抗体药物研发无疑是最受关注的焦点,是增长最快的细分领域之一,已成为生物药中最重要的一大品类。在抗体药物开发过程中,头对头的质量可比性研究更是重中之重。通常临床阶段及上市抗体药分子是大家首选的对标参照。

pages-1 3

缔码生物功能活性蛋白表达平台利用HEK293哺乳动物细胞分泌表达系统,重组表达了众多热门靶点的biosimilar参照抗体,便利广大科研工作者进行相关开发过程中的对比研究,同时也可以辅佐验证靶点蛋白的功能活性。

产品针对靶点: 

Product Targets

CD47IL6CD52
CD30CD20TNFRSF10B
CS1TIM3CD138CD40CD45
TweakR
CD123PDL1CD33MSLNTIGITCD22
CD38B7-H3CD27CTLA4BCMATIGIT
CD70GPRC5D
EPHA3Trop2EGFRAXL
PD-1ICOSCEACAM54-1BBIL17RANKG2D
CA9IL6RCD40LIL2RABAFFBAFFR
CD37
Find the right BMK antibody for your assay

产品数据展示:

活性蛋白检测

pages-2 4

Figure 1. ELISA plate pre-coated by 2 μg/ml (100 μl/well) Human PD1, mFc-His tagged protein (PME100025) can bind Anti-PD-1 Neutralizing antibody in a linear range of 0.24-6.49 ng/ml.

流式功能检测对比

pages-3 3

Figure 2. HEK293 cell line transfected with irrelevant protein (B) and human PD1(A) were surface stained with anti-PD1 neutralizing antibody 1μg/ml (pembrolizumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.

pages-88601cb58bcd430